Current therapies for premature ejaculation

GÜR S., Kadowitz P. J., Sikka S. C.

DRUG DISCOVERY TODAY, cilt.21, sa.7, ss.1147-1154, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 21 Sayı: 7
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1016/j.drudis.2016.05.004
  • Dergi Adı: DRUG DISCOVERY TODAY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1147-1154
  • Ankara Üniversitesi Adresli: Evet

Özet

Premature ejaculation (PE) subjectively affects 20-30% of men globally. Until recently, understanding of PE was hampered by the absence of a widely accepted definition, paucity of evidence-based clinical studies, and the absence of an appropriate animal model. Here, we elaborate on the current definition of PE, its pathogenesis, currently available therapies, and future treatment prospects. Most treatments for PE are 'off-label' and include selective serotonin reuptake inhibitors (SSRIs), topical anesthetics, tramadol, and phosphodiesterase type 5 (PDE5) inhibitors. Such knowledge of the benefit and limitations of each treatment will help to direct future drug design and formulations.